Welcome to our dedicated page for Immucell SEC filings (Ticker: ICCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImmuCell Corporation鈥檚 quest to keep dairy and beef calves healthy means its SEC disclosures cover everything from colostrum-based antibody sales to the status of Re-Tain, a non-antibiotic mastitis treatment now under FDA review. Whether you鈥檙e tracking bio-manufacturing capacity or weighing how feed-price cycles affect demand, the details you need live inside lengthy 10-Ks and a steady stream of 8-Ks. Stock Titan鈥檚 AI makes ImmuCell SEC filings explained simply, turning pages of veterinary science into plain-English insights.
Use our platform to move directly from question to answer. Curious about management鈥檚 growth assumptions? The ImmuCell annual report 10-K simplified highlights planned fermentation upgrades. Need segment revenue faster? The ImmuCell quarterly earnings report 10-Q filing is summarized line-by-line, and ImmuCell earnings report filing analysis spots margin shifts automatically. Material news such as FDA correspondence appears in an ImmuCell 8-K material events explained snapshot the moment it hits EDGAR.
Insider activity often tells its own story. Our real-time alerts track every ImmuCell insider trading Form 4 transactions, so you鈥檒l see ImmuCell Form 4 insider transactions real-time and understand which directors are buying dip or trimming gains. Drill deeper into governance through the ImmuCell proxy statement executive compensation section, or monitor ImmuCell executive stock transactions Form 4 for fresh context.
Behind each disclosure, Stock Titan layers AI-powered summaries, keyword search across all exhibits, and exportable tables, helping professionals:
- Compare quarter-over-quarter First Defense unit sales
- Monitor capital spending on the new Portland manufacturing suite
- Track regulatory milestones for Re-Tain without reading technical appendices
By understanding ImmuCell SEC documents with AI, you spend fewer hours sifting and more time deciding.
ImmuCell Corporation entered into a Loan Agreement and Promissory Note with Maine Community Bank for total loan proceeds of $2,327,119 at a fixed interest rate of 6.5% per annum. The proceeds were used to pay off an existing Maine Community Bank loan with an outstanding balance of $1,525,852 bearing interest at 7% and a Finance Authority of Maine loan with an outstanding balance of $768,209 bearing interest at 8%, effectively consolidating those obligations into a single loan.
The new loan is secured by a security interest in substantially all of the Company鈥檚 assets, and the lender may accelerate repayment if the Company fails to make timely payments or otherwise comply with the loan terms. The Loan Agreement and Promissory Note are filed as Exhibits 10.1 and 10.2, and a related press release is filed as Exhibit 99.1.
ImmuCell Corporation (NASDAQ:ICCC) filed an 8-K announcing the initiation of a CEO succession planning process. The filing discloses that current President and CEO Michael F. Brigham will be part of this transition. The company has begun searching for new leadership, though no specific timeline was provided. This represents a significant corporate governance development for ImmuCell, as leadership transitions can materially impact company strategy and operations.
FAQ
What is the current stock price of Immucell (ICCC)?
What is the market cap of Immucell (ICCC)?
